Eric S Schafer1,2, Rachel E Rau1,2, Stacey L Berg1,2, Xiaowei Liu3, Charles G Minard1, Alexander J R Bishop4,5, J Carolina Romero4, M John Hicks1, Marvin D Nelson6, Stephan Voss7, Joel M Reid8, Elizabeth Fox9, Brenda J Weigel10, Susan M Blaney1,2. 1. Baylor College of Medicine, Houston, Texas. 2. Texas Children's Cancer and Hematology Centers, Houston, Texas. 3. Children's Oncology Group, Monrovia, California. 4. Greehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, Texas. 5. Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, Texas. 6. Children's Hospital of Los Angeles, Los Angeles, California. 7. Dana Farber Cancer Institute, Boston, Massachusetts. 8. Mayo Clinic, Rochester, Minnesota. 9. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 10. University of Minnesota, Minneapolis, Minnesota.
Abstract
PURPOSE: We conducted a phase 1/2 trial of the poly(ADP-ribose) polymerase 1/2 inhibitor talazoparib in combination with low-dose temozolomide (TMZ) to determine the dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). METHODS: Talazoparib (400-600 µg/m2 /dose, maximum daily dose 800-1000 µg) was administered q.d. or b.i.d. orally on day 1 followed by q.d. dosing concomitant with q.d. dosing of oral TMZ (20-55 mg/m2 /day) on days 2 to 6, every 28 days. RESULTS: Forty patients, aged 4 to 25 years, were enrolled. Talazoparib was increased to 600 µg/m2 /dose b.i.d. on day 1, and q.d. thereafter, with 20 mg/m2 /day of TMZ, without DLTs. TMZ was subsequently increased, during which dose-limiting neutropenia and thrombocytopenia occurred in two of three subjects at 55 mg/m2 /day, two of six subjects at 40 mg/m2 /day, and one of six subjects at 30 mg/m2 /day. During dose-finding, two of five EWS and four of 25 non-EWS subjects experienced prolonged stable disease (SD), and one subject with malignant glioma experienced a partial response. In phase 2, 0 of 10 EWS subjects experienced an objective response; two experienced prolonged SD. CONCLUSIONS: Talazoparib and low-dose TMZ are tolerated in children with recurrent/refractory solid tumors. Reversible neutropenia and thrombocytopenia were dose limiting. The RP2D is talazoparib 600 µg/m2 b.i.d. on day 1 followed by 600 µg/m2 q.d. on days 2 to 6 (daily maximum 1000 µg) in combination with temozolomide 30 mg/m2 /day on days 2 to 6. Antitumor activity was not observed in EWS, and limited antitumor activity was observed in central nervous system tumors.
PURPOSE: We conducted a phase 1/2 trial of the poly(ADP-ribose) polymerase 1/2 inhibitor talazoparib in combination with low-dose temozolomide (TMZ) to determine the dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777). METHODS: Talazoparib (400-600 µg/m2 /dose, maximum daily dose 800-1000 µg) was administered q.d. or b.i.d. orally on day 1 followed by q.d. dosing concomitant with q.d. dosing of oral TMZ (20-55 mg/m2 /day) on days 2 to 6, every 28 days. RESULTS: Forty patients, aged 4 to 25 years, were enrolled. Talazoparib was increased to 600 µg/m2 /dose b.i.d. on day 1, and q.d. thereafter, with 20 mg/m2 /day of TMZ, without DLTs. TMZ was subsequently increased, during which dose-limiting neutropenia and thrombocytopenia occurred in two of three subjects at 55 mg/m2 /day, two of six subjects at 40 mg/m2 /day, and one of six subjects at 30 mg/m2 /day. During dose-finding, two of five EWS and four of 25 non-EWS subjects experienced prolonged stable disease (SD), and one subject with malignant glioma experienced a partial response. In phase 2, 0 of 10 EWS subjects experienced an objective response; two experienced prolonged SD. CONCLUSIONS: Talazoparib and low-dose TMZ are tolerated in children with recurrent/refractory solid tumors. Reversible neutropenia and thrombocytopenia were dose limiting. The RP2D is talazoparib 600 µg/m2 b.i.d. on day 1 followed by 600 µg/m2 q.d. on days 2 to 6 (daily maximum 1000 µg) in combination with temozolomide 30 mg/m2 /day on days 2 to 6. Antitumor activity was not observed in EWS, and limited antitumor activity was observed in central nervous system tumors.
Authors: Michèle Rouleau; Anand Patel; Michael J Hendzel; Scott H Kaufmann; Guy G Poirier Journal: Nat Rev Cancer Date: 2010-03-04 Impact factor: 60.716
Authors: Melanie L Bailey; Nigel J O'Neil; Derek M van Pel; David A Solomon; Todd Waldman; Philip Hieter Journal: Mol Cancer Ther Date: 2013-12-19 Impact factor: 6.261
Authors: Aparna Gorthi; July Carolina Romero; Eva Loranc; Lin Cao; Liesl A Lawrence; Elicia Goodale; Amanda Balboni Iniguez; Xavier Bernard; V Pragathi Masamsetti; Sydney Roston; Elizabeth R Lawlor; Jeffrey A Toretsky; Kimberly Stegmaier; Stephen L Lessnick; Yidong Chen; Alexander J R Bishop Journal: Nature Date: 2018-03-07 Impact factor: 49.962
Authors: Malcolm A Smith; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard B Lock; Stephen T Keir; John M Maris; Catherine A Billups; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton Journal: Clin Cancer Res Date: 2014-12-10 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Michelle A Rudek; Ross C Donehower; Paul Statkevich; Vijay K Batra; David L Cutler; Sharyn D Baker Journal: Pharmacotherapy Date: 2004-01 Impact factor: 4.705
Authors: Dannis G van Vuurden; Esther Hulleman; Olga L M Meijer; Laurine E Wedekind; Marcel Kool; Hendrik Witt; Peter W Vandertop; Thomas Würdinger; David P Noske; Gertjan J L Kaspers; Jacqueline Cloos Journal: Oncotarget Date: 2011-12
Authors: Shivaani Kummar; Alice Chen; Ralph E Parchment; Robert J Kinders; Jay Ji; Joseph E Tomaszewski; James H Doroshow Journal: BMC Med Date: 2012-03-09 Impact factor: 8.775
Authors: Andrew S Brohl; David A Solomon; Wendy Chang; Jianjun Wang; Young Song; Sivasish Sindiri; Rajesh Patidar; Laura Hurd; Li Chen; Jack F Shern; Hongling Liao; Xinyu Wen; Julia Gerard; Jung-Sik Kim; Jose Antonio Lopez Guerrero; Isidro Machado; Daniel H Wai; Piero Picci; Timothy Triche; Andrew E Horvai; Markku Miettinen; Jun S Wei; Daniel Catchpool; Antonio Llombart-Bosch; Todd Waldman; Javed Khan Journal: PLoS Genet Date: 2014-07-10 Impact factor: 5.917
Authors: Arthur Felix; Pablo Berlanga; Maud Toulmonde; Judith Landman-Parker; Sarah Dumont; Gilles Vassal; Marie-Cécile Le Deley; Nathalie Gaspar Journal: Cancer Med Date: 2021-01-15 Impact factor: 4.452
Authors: Holly L Pacenta; Wendy Allen-Rhoades; David Langenau; Peter J Houghton; Charles Keller; Christine M Heske; Michael D Deel; Corinne M Linardic; Jack F Shern; Elizabeth Stewart; Brian Turpin; Douglas J Harrison; Javed Khan; Leo Mascarenhas; Stephen X Skapek; William H Meyer; Douglas S Hawkins; Eleanor Y Chen; James F Amatruda; Pooja Hingorani; Theodore W Laetsch Journal: J Clin Med Date: 2021-04-01 Impact factor: 4.241
Authors: Marije E Weidema; Ingrid M E Desar; Melissa H S Hillebrandt-Roeffen; Anke E M van Erp; Mikio Masuzawa; Uta E Flucke; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers Journal: J Cancer Res Clin Oncol Date: 2021-06-03 Impact factor: 4.553
Authors: Vanessa Del Pozo; Andrew J Robles; Shaun D Fontaine; Qianqian Liu; Joel E Michalek; Peter J Houghton; Raushan T Kurmasheva Journal: iScience Date: 2021-12-31
Authors: Jeffrey C Martin; Tamara J Hoegel; Miranda L Lynch; Anna Woloszynska; Thomas Melendy; Joyce E Ohm Journal: Mol Cancer Res Date: 2020-10-05 Impact factor: 6.333